rs2293275 — LHCGR Asn312Ser (N312S)

LHCGR N312S — The LH Receptor Variant That Shapes Ovarian Sensitivity and Reproductive Aging

The luteinizing hormone/choriogonadotropin receptor (LHCGR) sits on the surface of ovarian theca cells, testicular Leydig cells, and luteinized granulosa cells, where it receives LH and hCG signals that drive ovulation, progesterone production, and testosterone synthesis. The N312S variant — a single amino acid change at position 312 from asparagine (N) to serine (S) — sits in exon 10 near a glycosylation site in the extracellular domain¹¹ near a glycosylation site in the extracellular domain
The asparagine at position 312 is a potential N-linked glycosylation sequon; replacing it with serine eliminates this site. This change alters receptor sensitivity to LH signaling, with measurable consequences for PCOS risk, ovarian reserve longevity, and IVF treatment response.

The Mechanism

LHCGR is a G protein-coupled receptor. When LH binds, the receptor activates Gs proteins, stimulating adenylyl cyclase to produce cAMP, which drives steroidogenesis and ovulation. The N312S variant changes a potential N-linked glycosylation site in the receptor's ectodomain. Asparagine (N) at position 312 can be glycosylated, while serine (S) cannot. In vitro studies of granulosa cells show that women homozygous for asparagine at both LHCGR 312 and FSHR 680 display lower cAMP activity²² In vitro studies of granulosa cells show that women homozygous for asparagine at both LHCGR 312 and FSHR 680 display lower cAMP activity
Reduced receptor signaling when both gonadotropin receptors carry the asparagine variant compared to serine homozygotes. The asparagine variant appears to create a receptor that is more sensitive to LH — requiring less LH to achieve the same downstream effect — which sounds advantageous but can dysregulate the tightly calibrated LH-FSH balance that governs normal follicular development.

The Evidence

PCOS risk. A 2012 case-control study in 198 PCOS and 187 control Sardinian women³³ A 2012 case-control study in 198 PCOS and 187 control Sardinian women
Capalbo et al. Clinical Endocrinology 2012 found that carrying at least one N allele (T on plus strand) increased PCOS risk 2-fold (OR 2.04, 95% CI 1.32–3.14, P=0.001), with NN homozygotes at 2.7-fold risk (OR 2.73, 95% CI 1.25–5.95, P=0.01). A 2015 Indian study⁴⁴ A 2015 Indian study
Thathapudi et al. Genetic Testing and Molecular Biomarkers found the SS genotype (GG on coding strand) associated with higher PCOS risk in their population (OR 3.36), elevated BMI, and higher LH/FSH ratios — though the direction of the risk allele differed from the Sardinian study, highlighting population heterogeneity. A recent meta-analysis of 10 studies (1,431 PCOS cases, 1,317 controls) found no significant overall association, suggesting the effect may be population-specific rather than universal.

Ovarian aging. A 2025 multicenter study of 1,240 Chinese women with diminished ovarian reserve or primary ovarian insufficiency⁵⁵ A 2025 multicenter study of 1,240 Chinese women with diminished ovarian reserve or primary ovarian insufficiency
Ma et al. Reproductive Biology and Endocrinology 2025 versus 72,846 controls found the TT genotype (NN) at 3.7-fold increased risk of POI (OR 3.73, 95% CI 2.09–6.67, P<0.001). Critically, TT carriers were diagnosed with POI approximately 7 years earlier (25.5 ± 6.4 years) than CC carriers (32.0 ± 5.1 years). The CT genotype (NS) also showed elevated DOR risk (OR 1.47, 95% CI 1.27–1.69). This large-scale finding positions LHCGR N312S as a potential biomarker for accelerated ovarian aging.

IVF outcomes. A prospective study of 617 IVF patients⁶⁶ A prospective study of 617 IVF patients
Lindgren et al. Human Reproduction 2016 found that LHCGR S312 carriers (C allele) had higher pregnancy rates (OR 1.61, P=0.008), and women homozygous for serine at both LHCGR and FSHR achieved dramatically higher pregnancy rates (OR 14.4, P=0.016). The follow-up study of 665 women⁷⁷ The follow-up study of 665 women
Lindgren et al. Journal of Assisted Reproduction and Genetics 2019 confirmed that women with 4 serine alleles across both receptors had a 62% cumulative live birth rate across three IVF cycles versus 43–47% for other genotypes (adjusted HR 1.89, P=0.049). Genotype-guided LH supplementation⁸⁸ Genotype-guided LH supplementation
Ramaraju et al. Frontiers in Endocrinology 2021 in 193 women showed improved pregnancy rates when LH dosing was matched to N312S genotype (P=0.049).

However, the evidence is not unanimous. A 2022 study of 1,183 patients⁹⁹ A 2022 study of 1,183 patients
Pirtea et al. Fertility and Sterility found no significant association between FSHR/LHCGR polymorphisms and oocyte yield, blastocyst rate, implantation, or live birth, concluding these variants "should not be considered reproductive predictors." This discrepancy may reflect differences in stimulation protocols, population composition, or the statistical power needed to detect interaction effects.

Practical Implications

The clinical utility of LHCGR N312S genotyping is strongest in two contexts: assessing PCOS risk and personalizing IVF protocols.

For women with TT (NN) genotype, the enhanced LH receptor sensitivity may contribute to the LH-driven androgen excess that characterizes PCOS. The 2025 Chinese study's finding of accelerated ovarian aging in TT carriers suggests this genotype warrants proactive ovarian reserve monitoring, particularly for women planning to delay childbearing.

For IVF, the interaction between LHCGR and FSHR genotypes defines a pharmacogenetic profile. Women with CC at both rs2293275 and rs6166 (SS at both receptors) appear to have an optimally responsive gonadal axis for ART, while TT carriers at LHCGR may benefit from adjusted LH supplementation protocols. The genotype-guided approach — withholding exogenous LH from NN carriers (whose receptors are already highly sensitive) and providing full-dose LH to SS carriers — showed promising results in the Ramaraju 2021 trial.

For men, LHCGR mediates LH signaling to Leydig cells for testosterone production. While specific rs2293275 data in male fertility is limited, the receptor's role in spermatogenesis makes this variant relevant to male reproductive assessment.

Interactions

FSHR rs6166 (N680S): The strongest documented interaction is with the FSH receptor N680S variant. Women homozygous for serine at both LHCGR N312S (CC genotype) and FSHR N680S (GG genotype) — the "4S" phenotype — had a 62% cumulative live birth rate across three IVF cycles versus 43–47% for other combined genotypes (adjusted HR 1.89, P=0.049). In vitro, granulosa cells from women homozygous for asparagine at both receptors showed lower cAMP activity, suggesting a combined receptor sensitivity profile. This interaction defines a pharmacogenetic subgroup: 4S women appear to respond particularly well to standard IVF protocols, while 4N women (TT at rs2293275 + AA at rs6166) may represent a distinct poor-response phenotype requiring protocol modification.

Compound implication for LHCGR TT + FSHR AA: Women carrying TT at rs2293275 and AA at rs6166 (4N phenotype) may have a combined receptor sensitivity profile that paradoxically impairs IVF response despite individually heightened receptor sensitivity. These women may benefit from modified stimulation protocols with carefully titrated gonadotropin dosing and extended monitoring. Conversely, the 4S phenotype (CC at rs2293275 + GG at rs6166) may represent the optimal pharmacogenetic profile for standard ART protocols.